Time has come for immunotherapy in PTCL
- PMID: 24832935
- DOI: 10.1182/blood-2014-04-565267
Time has come for immunotherapy in PTCL
Abstract
In this issue of Blood, Horwitz et al present encouraging results of a phase 2 study assessing the efficacy of the antibody-drug conjugate (ADC) brentuximab vedotin (BV) in relapsed/refractory peripheral T-cell lymphoma (PTCL).
Comment on
-
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.Blood. 2014 May 15;123(20):3095-100. doi: 10.1182/blood-2013-12-542142. Epub 2014 Mar 20. Blood. 2014. PMID: 24652992 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources